131 related articles for article (PubMed ID: 2323615)
41. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
[TBL] [Abstract][Full Text] [Related]
42. Intraperitoneal cytosine arabinoside administered in sequence with systemic cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Campora E; Bruzzone M; Chiara S; Alama A; Iskra L; Carnino F; Parodi S; Foglia G; Ragni N; Rosso R
Gynecol Oncol; 1990 Apr; 37(1):39-43. PubMed ID: 2323610
[TBL] [Abstract][Full Text] [Related]
43. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
Omura GA; Bundy BN; Berek JS; Curry S; Delgado G; Mortel R
J Clin Oncol; 1989 Apr; 7(4):457-65. PubMed ID: 2926470
[TBL] [Abstract][Full Text] [Related]
44. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC
Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657
[TBL] [Abstract][Full Text] [Related]
45. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.
Piver MS; Lele SB; Marchetti DL; Baker TR; Tsukada Y; Emrich LJ
J Clin Oncol; 1988 Jun; 6(6):983-9. PubMed ID: 3373267
[TBL] [Abstract][Full Text] [Related]
46. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
[TBL] [Abstract][Full Text] [Related]
47. Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer.
Massacesi C; Bascioni R; Cellerino R; Scartozzi M; Bracci R; Alessandroni P; Antognoli S; Ciavattini A; De Nictolis M; Piga A
J Exp Clin Cancer Res; 2000 Mar; 19(1):13-6. PubMed ID: 10840930
[TBL] [Abstract][Full Text] [Related]
48. Adjuvant cisplatin-based chemotherapy for stage I ovarian adenocarcinoma: a preliminary report.
Piver MS; Malfetano J; Baker TR; Lele SB; Marchetti DL
Gynecol Oncol; 1989 Oct; 35(1):69-72. PubMed ID: 2792905
[TBL] [Abstract][Full Text] [Related]
49. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
[TBL] [Abstract][Full Text] [Related]
50. Combined cyclophosphamide, adriamycin and cis-platinum in advanced ovarian cancer resistant to chlorambucil and cis-platinum.
Mann GJ; Malden LT; Solomon HJ; Tattersall MH
Gynecol Oncol; 1985 Jun; 21(2):215-9. PubMed ID: 3886497
[TBL] [Abstract][Full Text] [Related]
51. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma.
Fanning J; Bennett TZ; Hilgers RD
Obstet Gynecol; 1992 Dec; 80(6):954-60. PubMed ID: 1333066
[TBL] [Abstract][Full Text] [Related]
52. [Effectiveness of 3-drug therapy in patients with advanced ovarian cancer].
Kwaśniewska-Rokicińska C; Kaleta B; Kumor-Głodny T
Ginekol Pol; 1989 Feb; 60(2):86-9. PubMed ID: 2680790
[TBL] [Abstract][Full Text] [Related]
53. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
Alberts DS; Liu PY; Hannigan EV; O'Toole R; Williams SD; Young JA; Franklin EW; Clarke-Pearson DL; Malviya VK; DuBeshter B
N Engl J Med; 1996 Dec; 335(26):1950-5. PubMed ID: 8960474
[TBL] [Abstract][Full Text] [Related]
54. Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stages III and IV suboptimal disease ovarian cancer: a Southwest Oncology Group Study.
Alberts DS; Mason-Liddil N; O'Toole RV; Abbott TM; Kronmal R; Hilgers RD; Surwit EA; Eyre HJ; Baker LH
Gynecol Oncol; 1989 Jan; 32(1):8-15. PubMed ID: 2642455
[TBL] [Abstract][Full Text] [Related]
55. Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen.
Bruckner HW; Cohen CJ; Feuer E; Holland JF
Obstet Gynecol; 1989 Mar; 73(3 Pt 1):349-56. PubMed ID: 2492648
[TBL] [Abstract][Full Text] [Related]
56. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
J Clin Oncol; 1986 Jul; 4(7):1068-73. PubMed ID: 3723166
[TBL] [Abstract][Full Text] [Related]
57. Fist line chemotherapy in advanced ovarian cancer: a comparison of three therapeutic regimes.
Cherchi PL; Bagella MP; Campiglio A; Rubattu A; Farina M; Ambrosini A
Eur J Gynaecol Oncol; 1990; 11(6):453-6. PubMed ID: 2086227
[TBL] [Abstract][Full Text] [Related]
58. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer].
Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H
Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312
[TBL] [Abstract][Full Text] [Related]
59. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G
J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481
[TBL] [Abstract][Full Text] [Related]
60. [Multidisciplinary treatment of recurrent epithelial ovarian carcinoma and prognostic analysis].
Huang X; Cai SM; Tang J; Li ZT; Zang RY
Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):602-5. PubMed ID: 15498187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]